A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

Novel agents have provided new a foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Sher, Taimur, Ailawadhi, Sikander, Miller, Kena C., Manfredi, Debbie, Wood, Margaret, Tan, Wei, Wilding, Gregory, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J., Hong, Fredrick, Sood, Raman, Soniwala, Saif, Lawrence, William, Jamshed, Saad, Masood, Aisha, Iancu, Daniel, Lee, Kelvin, Chanan-Khan, Asher
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2011
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4078729/
https://ncbi.nlm.nih.gov/pubmed/21554260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08703.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk